ES2192611T3 - Procedimiento de eliminacion de la interferencia del factor reumatoide en los dosificados de diagnostico. - Google Patents

Procedimiento de eliminacion de la interferencia del factor reumatoide en los dosificados de diagnostico.

Info

Publication number
ES2192611T3
ES2192611T3 ES96927361T ES96927361T ES2192611T3 ES 2192611 T3 ES2192611 T3 ES 2192611T3 ES 96927361 T ES96927361 T ES 96927361T ES 96927361 T ES96927361 T ES 96927361T ES 2192611 T3 ES2192611 T3 ES 2192611T3
Authority
ES
Spain
Prior art keywords
solid phase
phase material
rheumatoid factors
igg antibodies
rheumatoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96927361T
Other languages
English (en)
Inventor
Jerzy A Macioszek
John M Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2192611T3 publication Critical patent/ES2192611T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces
    • Y10S435/902—Streptomyces olivaceus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/967—Standards, controls, materials, e.g. validation studies, buffer systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UN METODO PARA TRATAR MUESTRAS HUMANAS, POR EJEMPLO SUERO O PLASMA HUMANO, SOSPECHOSAS DE CONTENER FACTORES REUMATOIDES PARA ELIMINAR LOS RESULTADOS DE REACTIVIDAD CRUZADA Y FALSOS POSITIVOS EN LOS INMUNOENSAYOS DE IGM QUE ESTAN PROVOCADOS POR LA PRESENCIA DE FACTORES REUMATOIDES EN DICHAS MUESTRAS BIOLOGICAS. EN UN ASPECTO, EL METODO COMPRENDE LA DILUCION DE UNA MUESTRA BIOLOGICA CON UNA CANTIDAD SUFICIENTE DE UN TAMPON DE NEUTRALIZACION DE FACTOR REUMATOIDE PARA PROVOCAR QUE EL PH DE LAS MEZCLAS DE REACCION RESULTANTES QUE CONTIENEN ESTA MUESTRA Y UN MATERIAL DE FASE SOLIDA SEA LO SUFICIENTEMENTE BAJO PARA REDUCIR LA AFINIDAD DE LOS FACTORES REUMATOIDES EN DICHAS MEZCLAS POR ANTICUERPOS IGG A UN NIVEL TAL QUE NO FORMEN UN COMPLEJO CON ANTICUERPOS IGG UNIDOS AL MATERIAL DE FASE SOLIDA, FACILITANDO DE ESTE MODO LA ELIMINACION DE DICHOS FACTORES REUMATOIDES DE LAS MEZCLAS ANTES DE LA FASE DE DETECCION DE UN ENSAYO DE DIAGNOSTICO. EN OTRO ASPECTO DE LA INVENCION, EL METODO COMPRENDE INTRODUCIR EN UN MATERIAL DE FASE SOLIDA QUE COMPRENDE UN COMPLEJO DE ANTICUERPO MIEMBRO DE UNION UNA CANTIDAD SUFICIENTE DE UN TAMPON DE NEUTRALIZACION DE FACTOR REUMATOIDE PARA PROVOCAR QUE EL PH DE LAS MEZCLAS DE REACCION RESULTANTES QUE CONTIENEN ESTA MUESTRA Y UN MATERIAL DE FASE SOLIDA SEA LO SUFICIENTEMENTE BAJO PARA REDUCIR LA AFINIDAD DE FACTORES REUMATOIDES UNIDOS A ANTICUERPOS IGG UNIDOS AL MATERIAL DE FASE SOLIDA A LOS ANTICUERPOS IGG A UN NIVEL TAL QUE LOS FACTORES REUMATOIDES PUEDEN SER LAVADOS DEL MATERIAL DE FASE SOLIDA ANTES DE LA FASE DE DETECCION DE UN ENSAYO DIAGNOSTICO. EN CUALQUIERA DE LOS ASPECTOS, LAS CLASES DE TAMPONES QUE SON ADECUADAS PARA EL METODO DE ESTA INVENCION INCLUYEN TAMPONES IONICOS, NO IONICOS, Y ZWITTERIONICOS QUE POSEEN UN VALOR DE PKA NO SUPERIOR A APROXIMADAMENTE 6,5. LOS EJEMPLOS REPRESENTATIVOS DE LOS TAMPONES QUE SON ADECUADOS PARA EL METODO DE ESTA INVENCION INCLUYEN, PERO NO ESTAN LIMITADOS A, ACIDO ACETICO, ACIDO CITRICO, ACIDO FORMICO Y GLICINA.
ES96927361T 1995-08-18 1996-08-09 Procedimiento de eliminacion de la interferencia del factor reumatoide en los dosificados de diagnostico. Expired - Lifetime ES2192611T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/516,719 US5698393A (en) 1995-08-18 1995-08-18 Method for elimination of rheumatoid factor interference in diagnostic assays

Publications (1)

Publication Number Publication Date
ES2192611T3 true ES2192611T3 (es) 2003-10-16

Family

ID=24056820

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96927361T Expired - Lifetime ES2192611T3 (es) 1995-08-18 1996-08-09 Procedimiento de eliminacion de la interferencia del factor reumatoide en los dosificados de diagnostico.

Country Status (8)

Country Link
US (1) US5698393A (es)
EP (1) EP0846268B1 (es)
JP (1) JP3675837B2 (es)
AT (1) ATE231973T1 (es)
CA (1) CA2230644A1 (es)
DE (1) DE69626027T2 (es)
ES (1) ES2192611T3 (es)
WO (1) WO1997007401A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406844B1 (en) 1989-06-07 2002-06-18 Affymetrix, Inc. Very large scale immobilized polymer synthesis
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US6919211B1 (en) 1989-06-07 2005-07-19 Affymetrix, Inc. Polypeptide arrays
US6309822B1 (en) 1989-06-07 2001-10-30 Affymetrix, Inc. Method for comparing copy number of nucleic acid sequences
US6551784B2 (en) 1989-06-07 2003-04-22 Affymetrix Inc Method of comparing nucleic acid sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6346413B1 (en) 1989-06-07 2002-02-12 Affymetrix, Inc. Polymer arrays
US6955915B2 (en) 1989-06-07 2005-10-18 Affymetrix, Inc. Apparatus comprising polymers
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6416952B1 (en) 1989-06-07 2002-07-09 Affymetrix, Inc. Photolithographic and other means for manufacturing arrays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6506558B1 (en) 1990-03-07 2003-01-14 Affymetrix Inc. Very large scale immobilized polymer synthesis
EP0834575B1 (en) 1990-12-06 2001-11-28 Affymetrix, Inc. (a Delaware Corporation) Identification of nucleic acids in samples
US6468740B1 (en) 1992-11-05 2002-10-22 Affymetrix, Inc. Cyclic and substituted immobilized molecular synthesis
US6287850B1 (en) 1995-06-07 2001-09-11 Affymetrix, Inc. Bioarray chip reaction apparatus and its manufacture
US6121048A (en) * 1994-10-18 2000-09-19 Zaffaroni; Alejandro C. Method of conducting a plurality of reactions
US6720149B1 (en) * 1995-06-07 2004-04-13 Affymetrix, Inc. Methods for concurrently processing multiple biological chip assays
EP0957360B1 (de) * 1998-05-06 2002-07-31 Roche Diagnostics GmbH Entstörung durch Rheumafaktoren
US6545264B1 (en) 1998-10-30 2003-04-08 Affymetrix, Inc. Systems and methods for high performance scanning
WO2000033081A1 (en) 1998-12-01 2000-06-08 Viral Antigens, Inc. IMPROVED SPECIFICITY IN THE DETECTION OF ANTI-RUBELLA IgM ANTIBODIES
US6455007B1 (en) * 2000-06-13 2002-09-24 Symyx Technologies, Inc. Apparatus and method for testing compositions in contact with a porous medium
FR2864624A1 (fr) * 2003-12-24 2005-07-01 Inodiag Methode de diagnostic serologique des maladies infectieuses par immunodetection d'antigene microbien comprenant le controle de reaction faussement positive ou negative
US8445293B2 (en) 2005-02-09 2013-05-21 Rapid Pathogen Screening, Inc. Method to increase specificity and/or accuracy of lateral flow immunoassays
CN106290912A (zh) * 2016-08-12 2017-01-04 泰州泽成生物技术有限公司 一种IgM抗体检测用吸附剂及其制备方法
JPWO2025047641A1 (es) * 2023-08-25 2025-03-06

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008473B1 (en) * 1978-08-24 1983-06-01 Akzo N.V. Method for the detection and/or determination of an antigen specific immunoglobulin, immuno-reagents to be used in said method and test kit for said determination
US4292403A (en) * 1978-08-24 1981-09-29 Akzona Incorporated Detection and/or determination of IgM, IgA, IgD and IgE immunoglobulins
US4434227A (en) * 1982-02-08 1984-02-28 Abbott Laboratories Immunoassay for class specific immunoglobulin antibodies
IL80129A0 (en) * 1986-09-23 1986-12-31 Savyon Diagnostics Ltd Method for the determination of igm and iga immunoglobulins and reagents therefor
JPH0754322B2 (ja) * 1988-11-07 1995-06-07 三洋化成工業株式会社 免疫学的定量法および検査用試薬
US5556745A (en) * 1994-06-03 1996-09-17 Sch+E,Uml U+Ee Pbach; J+E,Uml O+Ee Rg Method for the detection and quantitative determination of antigen in a test sample containing immune complexes of antigen bound to antibodies and to rheumatoid factors

Also Published As

Publication number Publication date
JP3675837B2 (ja) 2005-07-27
DE69626027D1 (de) 2003-03-06
CA2230644A1 (en) 1997-02-27
ATE231973T1 (de) 2003-02-15
EP0846268A1 (en) 1998-06-10
JPH11511255A (ja) 1999-09-28
US5698393A (en) 1997-12-16
WO1997007401A1 (en) 1997-02-27
DE69626027T2 (de) 2003-11-20
EP0846268B1 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
ES2192611T3 (es) Procedimiento de eliminacion de la interferencia del factor reumatoide en los dosificados de diagnostico.
DK1125130T3 (da) Påvisning af syreresistente mikroorganismer i afföringen
PT1232392E (pt) Processo melhorado para deteccao nas fezes de bacterias do genero helicobacter resistentes ao acido
DE68928007D1 (de) Antigene Zusammensetzungen aus Fragmenten von Campylobacter pylori und Verfahren zu ihrer Herstellung und Verwendung
DE68928427D1 (de) Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
DE69113273D1 (de) Zellnekrosnachweis durch prüfung von spektrin und seine abbauprodukte.
KR960029789A (ko) 생체내 물질의 면역학적 분석용 키트 및 면역학적 분석 방법
NO821431L (no) Fremgangsmaate og sett for proeving av antilegemer mot antigener
ZA90136B (en) Diagnostic test using chimeric antibodies
EP0174652A3 (en) Immunochemical test process for hapteus and proteins
DE59609578D1 (de) Verfahren und mittel zum nachweis von antikörpern gegen treponema pallidum
ATE397215T1 (de) Entstörung von immunoassays durch substanzen, die aus den framework-regionen von antikörpern abgeleitet sind
DK0725837T3 (da) Adeno-associeret virus - dettes diagnostiske anvendelse ved tidlig abort
DE59510868D1 (de) Oligomere trägermoleküle mit definiert eingebauten markierungsgruppen und haptenen
ATE185900T1 (de) Festphasen-filtrationsverfahren zur antigen- und antikörperprüfung in der blutgruppen-serologie, und testsatz
EP0254081A3 (en) Method of detecting specific protein
ATE112392T1 (de) Agglutinationskomplex zum nachweis von blutgruppen.
DE50101435D1 (de) Verfahren zum nachweis von helicobacter pylori und heilmanii
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
DE59309999D1 (de) Verfahren zum Nachweisen von Antikörpern und Antigenen
RU2152036C1 (ru) Способ определения и дифференциации ботулинических токсинов типов а и в
NO964279L (no) Deteksjonsreagenser for sporsubstanser, samt fremgangsmåte ved påvisning av rheumatoid artritt
SU1749758A1 (ru) Способ обнаружени эндотоксинов грамотрицательных бактерий
Lelong et al. Solid immunoassay and immunonephelemetric methods for serum C reactive protein (CRP) determination: discrepancy in CRP value for a patient presenting a monoclonal immunoglobulin G
RU97105592A (ru) Способ количественного определения аутоантител к липопротеидам низкой плотности в сыворотке крови